ES2331119T3 - Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa. - Google Patents

Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa. Download PDF

Info

Publication number
ES2331119T3
ES2331119T3 ES03778283T ES03778283T ES2331119T3 ES 2331119 T3 ES2331119 T3 ES 2331119T3 ES 03778283 T ES03778283 T ES 03778283T ES 03778283 T ES03778283 T ES 03778283T ES 2331119 T3 ES2331119 T3 ES 2331119T3
Authority
ES
Spain
Prior art keywords
methyl
ethyl
pyrazolo
pyridine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03778283T
Other languages
English (en)
Spanish (es)
Inventor
David George Allen
Diane Mary Coe
Caroline Mary Cook
Michael Dennis Dowle
Christopher David Edlin
Julie Nicole Hamblin
Martin Redpath Johnson
Paul Spencer Jones
Richard Graham Knowles
Mika Kristian Lindvall
Charlotte Jane Mitchell
Alison Judith Redgrave
Peter Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0221455A external-priority patent/GB0221455D0/en
Priority claimed from GBGB0230045.7A external-priority patent/GB0230045D0/en
Priority claimed from GB0306595A external-priority patent/GB0306595D0/en
Priority claimed from GB0308017A external-priority patent/GB0308017D0/en
Priority claimed from GB0319708A external-priority patent/GB0319708D0/en
Priority claimed from GB0321074A external-priority patent/GB0321074D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2331119T3 publication Critical patent/ES2331119T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES03778283T 2002-09-16 2003-09-12 Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa. Expired - Lifetime ES2331119T3 (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0221455A GB0221455D0 (en) 2002-09-16 2002-09-16 Compounds
GB0221455 2002-09-16
GBGB0230045.7A GB0230045D0 (en) 2002-12-23 2002-12-23 Compounds
GB0230045 2002-12-23
GB0306595A GB0306595D0 (en) 2003-03-21 2003-03-21 Compounds
GB0306595 2003-03-21
GB0308017A GB0308017D0 (en) 2003-04-07 2003-04-07 Compounds
GB0308017 2003-04-07
GB0319708 2003-08-21
GB0319708A GB0319708D0 (en) 2003-08-21 2003-08-21 Compounds
GB0321074A GB0321074D0 (en) 2003-09-09 2003-09-09 Compounds
GB0321074 2003-09-09
PCT/EP2003/011814 WO2004024728A2 (en) 2002-09-16 2003-09-12 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
ES2331119T3 true ES2331119T3 (es) 2009-12-22

Family

ID=31999797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03778283T Expired - Lifetime ES2331119T3 (es) 2002-09-16 2003-09-12 Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.

Country Status (23)

Country Link
US (2) US20060089375A1 (ja)
EP (1) EP1539753B1 (ja)
JP (1) JP2006503108A (ja)
KR (1) KR20050052501A (ja)
CN (1) CN100387598C (ja)
AT (1) ATE442367T1 (ja)
AU (1) AU2010201417A1 (ja)
BR (1) BR0314392A (ja)
CA (1) CA2497550A1 (ja)
CY (1) CY1109619T1 (ja)
DE (1) DE60329193D1 (ja)
DK (1) DK1539753T3 (ja)
ES (1) ES2331119T3 (ja)
IL (1) IL166898A (ja)
IS (1) IS7709A (ja)
MA (1) MA27475A1 (ja)
MX (1) MXPA05002887A (ja)
NO (1) NO20050841L (ja)
NZ (1) NZ538515A (ja)
PL (1) PL375993A1 (ja)
PT (1) PT1539753E (ja)
SI (1) SI1539753T1 (ja)
WO (1) WO2004024728A2 (ja)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331119T3 (es) * 2002-09-16 2009-12-22 Glaxo Group Limited Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2004096130A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
JP2007514704A (ja) * 2003-12-19 2007-06-07 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびホスホジエステラーゼ阻害剤としてのその使用
EP1735314A1 (en) * 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
GB0405933D0 (en) * 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
BRPI0509382A (pt) 2004-04-02 2007-09-18 Glaxo Group Ltd processo para a preparação de um sal monocloridrato de composto, monocloridrato cristalino, processo para obter monocloridrato cristalino, método para a profilaxia ou o tratamento de uma condição clìnica em um mamìfero, uso de monocloridrato cristalino, formulação farmacêutica, e, combinação
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006004188A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrazolopyridine derivatives
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007036734A1 (en) * 2005-09-29 2007-04-05 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
CA2649509A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
JP2009545579A (ja) 2006-08-01 2009-12-24 グラクソ グループ リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物、及びｐｄｅ４阻害薬としてのその使用
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2009041591A1 (ja) * 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
CL2009000249A1 (es) * 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411516A1 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
CA2756069A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1)gene expression using short interfering nucleic acid (sina)
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
PL2899191T3 (pl) 2009-04-30 2018-01-31 Glaxo Group Ltd Indazole podstawione oksazolem jako inhibitory kinazy PI3
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CN102485724B (zh) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 取代噻吩基吡唑并吡啶类化合物及其医药用途
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
JP2016537327A (ja) 2013-10-17 2016-12-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
CN106163521B (zh) 2014-03-27 2021-02-09 艾科西斯有限责任公司 有效的可溶性环氧化物水解酶抑制剂
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
EA201692111A1 (ru) 2014-05-12 2017-08-31 Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
KR102089254B1 (ko) 2015-05-12 2020-03-16 다이호야쿠힌고교 가부시키가이샤 아자 2 고리형 화합물의 결정
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
CN107964011A (zh) * 2016-10-19 2018-04-27 中国人民解放军军事医学科学院毒物药物研究所 取代吡唑并吡啶类衍生物及其医药用途
MX2019007803A (es) 2016-12-28 2019-08-29 Dart Neuroscience Llc Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3682881A4 (en) 2017-09-14 2021-08-11 Daiichi Sankyo Company, Limited CONNECTION WITH CYCLICAL STRUCTURE
EP4155300A1 (en) 2017-10-30 2023-03-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Substituted quinoline analogs as aldehyde dehydrogenase 1a1 (aldh1a1) inhibitors
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物
AU2021338837A1 (en) 2020-09-10 2023-04-06 Vanda Pharmaceuticals Inc. Methods of treating PDE IV mediated diseases or conditions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598838A (en) * 1898-02-08 William b
US598973A (en) * 1898-02-15 Water-heater and smoke-consumer
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US4012373A (en) * 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) * 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
ES2331119T3 (es) * 2002-09-16 2009-12-22 Glaxo Group Limited Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP2007514704A (ja) * 2003-12-19 2007-06-07 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびホスホジエステラーゼ阻害剤としてのその使用

Also Published As

Publication number Publication date
CY1109619T1 (el) 2014-08-13
DE60329193D1 (de) 2009-10-22
AU2010201417A1 (en) 2010-04-29
DK1539753T3 (da) 2010-01-04
IL166898A (en) 2010-06-30
WO2004024728A3 (en) 2004-10-21
US20080175914A1 (en) 2008-07-24
EP1539753B1 (en) 2009-09-09
CN100387598C (zh) 2008-05-14
CN1694882A (zh) 2005-11-09
WO2004024728A2 (en) 2004-03-25
CA2497550A1 (en) 2004-03-25
JP2006503108A (ja) 2006-01-26
NO20050841L (no) 2005-06-15
AU2003285300A1 (en) 2004-04-30
PL375993A1 (en) 2005-12-12
PT1539753E (pt) 2009-12-10
NZ538515A (en) 2007-04-27
EP1539753A2 (en) 2005-06-15
IS7709A (is) 2005-02-24
ATE442367T1 (de) 2009-09-15
SI1539753T1 (sl) 2009-12-31
MXPA05002887A (es) 2005-05-27
US20060089375A1 (en) 2006-04-27
BR0314392A (pt) 2005-07-12
KR20050052501A (ko) 2005-06-02
MA27475A1 (fr) 2005-08-01

Similar Documents

Publication Publication Date Title
ES2331119T3 (es) Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
ES2345385T3 (es) Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
ES2363795T3 (es) Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4.
US7465743B2 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
US20070111995A1 (en) Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
KR20060130744A (ko) 피라졸로［３，４―ｂ］피리딘 화합물 및 이의 ｐｄｅ４억제제로서의 용도
US20090326003A1 (en) Pyrazolo (3, 4-b) pyridine derivatives as pde4 inhibitors
RU2357967C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[3, 4-b]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ), ПРИМЕНЕНИЕ (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ)
TWI283678B (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
ES2362445T3 (es) Compuestos de pirazolo[3,4-b]piridina y su uso como inhibidores de pde4.
AU2003285300B2 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
MXPA06010486A (en) Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
EP1737857A1 (en) Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors